Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
Noosa News23 hours agoThe Brisbane state school with an IB program preparing students for university
-
General23 hours agoThe ghost of Gough Whitlam is dead
-
General14 hours agoMillennials and Gen Z voters continued shift away from Coalition in 2025
-
General22 hours agoDonald Trump pardons Rudy Giuliani and others involved in trying to overturn 2020 election